In this micro learning developed by experts Prof. Aiwu Ruth He and Prof. Beau Toskich, you’ll learn about the expanding role of immunotherapy (IO) in hepatocellular carcinoma (HCC) and treatment strategies of combining it with locoregional therapy (LRT) for patients with intermediate HCC.
The module features a concise animated video, downloadable resources, and an assessment to evaluate your understanding.
Topics include the following:
- The role of IO and IO combinations in the systemic treatment landscape for unresectable HCC
- The scientific rationale for and the expanding role of IO, including multimodal approaches for intermediate HCC
- The safety and efficacy of IO and IO-based treatments in combination with locoregional therapies
- The importance of multidisciplinary care to optimise treatment
Micro learning programmes offer concise, easily digestible resources, each lasting under five minutes to watch or read. If you have extra time, complete the short assessment and earn CME credit in just 30 minutes.
Clinical takeaways
- IO and IO combinations are transforming the landscape for patients with advanced and intermediate HCC who are not candidates for local therapy, with 1st line options (IMbrave150, HIMALAYA) offering improved long-term outcomes, including 20% survival at 5-years in HIMALAYA
- Intermediate-stage HCC may benefit from multimodal strategies, combining IO with LRTs to address both visible and invisible disease, enhancing immune response and optimising tumour control
- IO + LRT combinations, such as TACE plus IO, show promise for patients with intermediate HCC, with positive trials like EMERALD-1 and LEAP-012 demonstrating improved PFS and manageable safety profiles, with ongoing evaluation of OS outcomes
- A multidisciplinary approach is crucial to determine which patients with intermediate HCC may benefit from multimodal combinations, requiring coordination among oncologists, hepatologists, interventional radiologists, radiation oncologists, and transplant surgeons